最新观点
Insights From Our Experts
Articles
QUIZ: How Mature Are Your HCP & Patient Engagement Strategies?
In the increasingly virtual world we live in, there’s no denying the instrumental role that technology plays in engaging patients and healthcare providers (HCPs). With heavier reliance across industries on text alerts, automated phone reminders and…
A YEAR OF ACTION: Why Data-Backed, Integrated Commercialization Strategies Are Must-haves in 2022
By applying transformative commercialization models, nurturing digital transformation and trailblazing in global expansion, we can get therapies to patients around the world who are still waiting for treatment options. For the past two years, the pharmaceutical…
The Power to Know When: Balancing High-Tech and High-Touch Solutions to Eliminate Access, Affordability and Adherence Barriers
Forty percent of consumers prefer speaking to a real person on the phone, and for more complex issues, 80% want to speak to a live service agent. In the increasingly virtual world we live in, one…
Why Launching in Europe Is Unlike Launching Anywhere Else
Today, there are more than half a billion people in the European Union (EU) and United Kingdom (U.K.). Passing over this part of the globe puts patients and manufacturers at risk for negative outcomes. Launching a…
Launch Sequencing and Market Prioritization in an Evolving Global Market
The world is facing a multitude of governing and legislative changes that will directly affect pharmaceutical pricing in the coming years, with many of these changes exacerbated by the pandemic. As countries become increasingly interconnected, decisions…
Aligning Net Pricing with Patient Outcomes – Removing Barriers to Value-Based Contracting
While value-based contracting has long been heralded as a way to ensure the cost of life-changing and life-saving medicines are aligned with patient outcomes, the complexity in their implementation has limited adoption to just a few…
30 Years of Insights: A look into the future of research and insights and the need for connectivity to navigate market access challenges
Thirty years ago, the industry faced a new problem: Pharmacy benefit managers were wreaking havoc by negotiating and controlling drug spending with pharmaceutical companies and pharmacies. This resulted in a significant behind-the-scenes impact in determining total…
Rx-to-OTC Switch Tips: Identifying the Right Timing, Conditions, and Approach for Rx-to-OTC Conversion
Exploring the idea of converting a prescription (Rx) drug to an over-the-counter (OTC) product can be a useful part of life cycle management and loss of exclusivity planning. However, while an Rx-to-OTC switch could provide significant…
Options and Insights for Successful Development and Launch
Pharma Sponsored Digital Health Solutions and Digital Therapeutics (DTx): Options and Insights for Successful Development and Launch Listen to EVERSANA’s Scott Snyder and Jim O’Donoghue of S3 Connected Health in this recorded webinar as they share insights on the driving…
Considering Commercial Success During Clinical Development: Maintaining a Global Perspective
Posted by
Melissa Thompson, B.Sc., MBA , Mike Ryan , Adam Hardy , Ari Mendell, MSc, PhD , Joshua Gauci , Nicole Hengst on 12 月 6, 202112/6/21
Although commercial success is the ultimate goal of pharmaceutical research and development (R&D), many new treatments do not meet expectations and fail to achieve broad global reimbursement after initial regulatory approval., This causes therapies to underperform across international markets…